Is HPS2-THRIVE the death knell for niacin?

Journal of Clinical Lipidology

Volumn 9, Issue 3, 2015, Pages 343-350

  Toth, Peter P ^a,b   Murthy, Avinash M ^c   Sidhu, Mandeep S ^d   Boden, William E ^d  

^a CGH Medical Center   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Atherosclerosis; Coronary artery disease; High density lipoprotein cholesterol; Niacin; Statin

Indexed keywords

ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; ANTILIPEMIC AGENT;

ACUTE CORONARY SYNDROME; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROTIC PLAQUE; BODY MASS; CARDIAC PATIENT; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; DRUG ELUTING STENT; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INSULIN RESISTANCE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; SECONDARY PREVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; BLOOD; CLINICAL TRIAL (TOPIC); MYOCARDIAL INFARCTION;

CLINICAL TRIALS AS TOPIC; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NIACIN;

EID: 84931565856     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2015.01.008     Document Type: Article

References (54)

1. W.E. Boden, J.L. Probstfield, and T. Anderson Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
2. HPS-2 Thrive Collaborative Group HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur Heart J 34 2013 1279 1291
3. HPS-2 THRIVE Collaborative Group Effects of extended-release niacin with laropiprant in high-risk patients N Engl J Med 371 2014 203 212
4. C. Baigent, A. Keech, and P.M. Kearney Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
5. Cholesterol Treatment Trialists C C. Baigent, L. Blackwell, and J. Emberson Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
6. J. Armitage, L. Bowman, and K. Wallendszus Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial Lancet 376 2010 1658 1669
7. M.J. Cziraky, K.E. Watson, and R.L. Talbert Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting J Manag Care Pharm 14 2008 S3 S28
8. E.S. Ford, W.H. Giles, and W.H. Dietz Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey JAMA 287 2002 356 359
9. T. Gordon, W.P. Castelli, M.C. Hjortland, W.B. Kannel, and T.R. Dawber High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study Am J Med 62 1977 707 714
10. W.P. Castelli Cholesterol and lipids in the risk of coronary artery disease-the Framingham Heart Study Can J Cardiol 4 Suppl A 1988 5A 10A
11. J. Pekkanen, S. Linn, and G. Heiss Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease N Engl J Med 322 1990 1700 1707
12. R.M. Wolfram, H.B. Brewer, and Z. Xue Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation Am J Cardiol 98 2006 711 717
13. H.B. Rubins, S.J. Robins, and D. Collins Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group Am J Cardiol 75 1995 1196 1201
14. H.B. Rubins, S.J. Robins, and D. Collins Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group N Engl J Med 341 1999 410 418
15. Coronary Drug Project Investigators Clofibrate and niacin in coronary heart disease JAMA 231 1975 360 381
16. K.G. Berge, and P.L. Canner Coronary drug project: experience with niacin. Coronary Drug Project Research Group Eur J Clin Pharmacol 40 Suppl 1 1991 S49 S51
17. D.H. Blankenhorn, S.A. Nessim, R.L. Johnson, M.E. Sanmarco, S.P. Azen, and L. Cashin-Hemphill Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts JAMA 257 1987 3233 3240
18. J.P. Kane, M.J. Malloy, T.A. Ports, N.R. Phillips, J.C. Diehl, and R.J. Havel Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens JAMA 264 1990 3007 3012
19. G. Brown, J.J. Albers, and L.D. Fisher Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B N Engl J Med 323 1990 1289 1298
20. B.G. Brown, X.Q. Zhao, and A. Chait Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 2001 1583 1592
21. A.J. Taylor, T.C. Villines, and E.J. Stanek Extended-release niacin or ezetimibe and carotid intima-media thickness N Engl J Med 361 2009 2113 2122
22. J.R. Guyton, A.E. Slee, and T. Anderson Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes) J Am Coll Cardiol 62 2013 1580 1584
23. S. Kamath, A.D. Blann, and G.Y. Lip Platelet activation: assessment and quantification Eur Heart J 22 2001 1561 1571
24. R.S. Rosenson Antiatherothrombotic effects of nicotinic acid Atherosclerosis 171 2003 87 96
25. A. Warnholtz, P. Wild, and M.A. Ostad Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study Atherosclerosis 204 2009 216 221
26. U. Landmesser The difficult search for a 'partner' of statins in lipid-targeted prevention of vascular events: the re-emergence and fall of niacin Eur Heart J 34 2013 1254 1257
27. B.J. Wu, L. Yan, F. Charlton, P. Witting, P.J. Barter, and K.A. Rye Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids Arterioscler Thromb Vasc Biol 30 2010 968 975
28. D.L. Sprecher Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review Am J Cardiol 86 2000 46L 50L
29. P.M. Lavigne, and R.H. Karas The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression J Am Coll Cardiol 61 2013 440 446
30. J.T. Kuvin, D.M. Dave, and K.A. Sliney Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease Am J Cardiol 98 2006 743 745
31. S. Acharjee, W.E. Boden, and P.M. Hartigan Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: a post-hoc analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) J Am Coll Cardiol 62 2013 1826 1833
32. S. Acharjee, M.T. Roe, E.A. Amsterdam, D.N. Holmes, and W.E. Boden Relation of admission high-density lipoprotein cholesterol level and in-hospital mortality in patients with acute non-ST segment elevation myocardial infarction (from the National Cardiovascular Data Registry) Am J Cardiol 112 2013 1057 1062
33. P.H. Joshi, P.P. Toth, and S.T. Lirette Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies Eur J Prev Cardiol 2014 pii: 2047487314543890. [Epub ahead of print]
34. S.S. Martin, S.R. Jones, and P.P. Toth High-density lipoprotein subfractions: current views and clinical practice applications Trends Endocrinol Metab 25 2014 329 336
35. S.S. Martin, A.A. Khokhar, and H.T. May HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative Eur Heart J 36 1 2015 22 30
36. M. Rizzo, J. Otvos, D. Nikolic, G. Montalto, P.P. Toth, and M. Banach Subfractions and subpopulations of HDL: an update Curr Med Chem 21 2014 2881 2891
37. A. Kontush, M. Lhomme, and M.J. Chapman Unraveling the complexities of the HDL lipidome J Lipid Res 54 2013 2950 2963
38. S.M. Gordon, J. Deng, L.J. Lu, and W.S. Davidson Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography J Proteome Res 9 2010 5239 5249
39. A.V. Khera, M. Cuchel, and M. de la Llera-Moya Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis N Engl J Med 364 2011 127 135
40. A. Rohatgi, A. Khera, and J.D. Berry HDL cholesterol efflux capacity and incident cardiovascular events N Engl J Med 371 2014 2383 2393
41. A.V. Khera, P.J. Patel, M.P. Reilly, and D.J. Rader The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality J Am Coll Cardiol 62 2013 1909 1910
42. W.E. Boden, M.S. Sidhu, and P.P. Toth The therapeutic role of niacin in dyslipidemia management J Cardiovasc Pharmacol Ther 19 2014 141 158
43. H.N. Ginsberg, M.B. Elam, and L.C. Lovato Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
44. P.E. Linz, L.C. Lovato, and R.P. Byington Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial Diabetes Care 37 2014 686 693
45. A. Zambon, X.Q. Zhao, B.G. Brown, and J.D. Brunzell Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease Am J Cardiol 113 2014 1494 1498
46. N.J. Stone, J.G. Robinson, and A.H. Lichtenstein 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 129 2014 S1 45
47. P.P. Toth, P.J. Barter, and R.S. Rosenson High-density lipoproteins: a consensus statement from the National Lipid Association J Clin Lipidol 7 2013 484 525
48. A. Varbo, M. Benn, A. Tybjaerg-Hansen, A.B. Jorgensen, R. Frikke-Schmidt, and B.G. Nordestgaard Remnant cholesterol as a causal risk factor for ischemic heart disease J Am Coll Cardiol 61 2013 427 436
49. A. Varbo, M. Benn, A. Tybjaerg-Hansen, and B.G. Nordestgaard Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation Circulation 128 2013 1298 1309
50. P.P. Toth, J. Massaro, and S. Jones Quantitative impact of remnant lipoproteins on risk for hard CHD events: a meta-analysis of the Framingham Offspring and Jackson Heart Studies J Am Coll Cardiol 63 2014 (12S)
51. T.A. Jacobson, M.K. Ito, and K.C. Maki National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1-executive summary J Clin Lipidol 8 2014 473 488
52. S.M. Grundy, H. Arai, and P. Barter An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia-full report J Clin Lipidol 8 2014 29 60
53. T.J. Anderson, J. Grégoire, and R.A. Hegele 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult Can J Cardiol 29 2013 151 167
54. Z. Reiner, A.L. Catapano, and G. De Backer ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 32 2011 1769 1818